|
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada |
Muszbek N, Shah S, Carroll S, McDonald H, Dale P, Maroun J, Knox J |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Muszbek N, Shah S, Carroll S, McDonald H, Dale P, Maroun J, Knox J. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Current Medical Research and Opinion 2008; 24(12): 3559-3569 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /administration & Benzenesulfonates /administration & Canada; Carcinoma, Hepatocellular /drug therapy /economics /mortality; Disease-Free Survival; Europe; Humans; Liver Neoplasms /drug therapy /economics /mortality; Markov Chains; Models, Theoretical; Niacinamide /analogs & Phenylurea Compounds; Pyridines /administration & Sensitivity and Specificity; Survival Rate; derivatives; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22009101241 Date bibliographic record published 09/09/2009 |
|
|
|